|
목적 : To evaluate the long term functional and anatomical outcome of combined intravitreal bevacizumab injection and laser indirect ophthalmoscope (LIO) in infants with “high risk” type 1 retinopathy of prematurity (ROP) and systemic development, comparing with the treatment results in infants treated with LIO only.
방법 : The medical records of 14 eyes of 7 infants who underwent combined intravitreal bevacizumab (0.5mg/0.02ml) injection and LIO (Group 1) and of 18 eyes of 9 infants who underwent LIO only (Group 2) for the treatment of type 1 ROP were retrospectively chart-reviewed. Anatomical outcomes including progression to stage 4 or 5, vitreous organization, macular changes, additional LIO or vitrectomy were reviewed. About ocular function and systemic development, the primary outcome measure was visual acuity and secondary outcomes were other ocular functional measurements, and developmental state.
결과 : Mean GA(weeks)was 25.2,and 26.2 for each group, respectively.(p= 0.114) and mean birth weight (g)was741 and 865.4 (p =0.299).Mean follow-up period(months)was 27.42 and 34.Final mean BCVA(logMAR)were 0.6±0.31and0.56±0.31(p=0.776).In group1,five infants with strabismus (mean 13.1 PD) was under conservative treatment, but in group 2, three out of four infants (mean 14 PD) had operation. Two patients in group1(one spinal cord atrophy and one developmental delay in language and social)and three patients in group 2 (two cerebral palsy,one delayed congnitivefunction) showed delay in neurodevlopment
결론 : In the infants with “high risk“ type I ROP, combined intravitreal bevacizumab and LIO seems to bring equivalent outcomes with LIO only in terms of ocular and systemic outcome. However, long-term, larger, prospective, controlled, randomized trials are needed to prove the safety and efficacy of intravitreal bevacizumab in infants with ROP.
|